2023 World Conference on Lung Cancer (Posters)-P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations

P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations - PDF(Slides)

Back to course

Pdf Summary

Lung cancer is the most common and deadly form of cancer globally, as well as in Vietnam. The treatment landscape for non-small cell lung cancer (NSCLC) has seen significant advancements in recent years, particularly with the use of Tyrosine Kinase inhibitors (TKIs) for patients with EGFR mutations. Studies have shown that Afatinib, a TKI, has provided better treatment outcomes compared to chemotherapy for NSCLC patients with EGFR mutations. Real-world studies conducted in Asia have also demonstrated the efficacy of Afatinib in patients with uncommon EGFR mutations.<br /><br />However, in Vietnam, most studies on Afatinib's therapeutic efficacy have been conducted in single centers, limiting the sample size and representativeness of the whole country. This study aimed to evaluate the outcomes of first-line treatment with Afatinib in patients with advanced NSCLC and uncommon EGFR mutations in Vietnam.<br /><br />A total of 92 patients were included in the study, with a median age of 63 years and a majority of them being male. The study found that the overall response rate to Afatinib treatment was 75%, with a disease control rate of 89.1%. The median time to treatment failure was 13.8 months, with patients carrying G719X mutations or compound mutations of G719X and S768I showing longer median times to treatment failure compared to patients with other mutations.<br /><br />Adverse events related to Afatinib treatment were also recorded, with rash being the most common side effect. Other adverse events included diarrhea, paronychia, and increased liver enzymes.<br /><br />In conclusion, Afatinib was found to be an effective treatment option for patients with advanced NSCLC and uncommon EGFR mutations in Vietnam. Patients carrying specific mutations or treated with a tolerated dose of 20mg or 30mg had longer median times to treatment failure. These findings contribute to the growing body of evidence supporting the use of Afatinib in the treatment of NSCLC patients with EGFR mutations.

Asset Subtitle

Luan Pham

Meta Tag

Speaker Luan Pham

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lung cancer

NSCLC

Tyrosine Kinase inhibitors

EGFR mutations

Afatinib

chemotherapy

treatment outcomes

Vietnam

advanced NSCLC

uncommon EGFR mutations